This shows you the differences between two versions of the page.
Previous revision | |||
— | home:publications:proal_molecular_2011 [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 1: | Line 1: | ||
+ | | ||
+ | |||
+ | **Type:** Paper\\ | ||
+ | **Authors: | ||
+ | **Publication: | ||
+ | **Citation: | ||
+ | **See also:** [[https:// | ||
+ | |||
+ | < | ||
+ | < | ||
+ | <a href=" | ||
+ | </ | ||
+ | |||
+ | |||
+ | <a href=" | ||
+ | |||
+ | |||
+ | </ | ||
+ | |||
+ | |||
+ | ===== Abstract ===== | ||
+ | |||
+ | Microbes are increasingly being implicated in autoimmune disease. This calls for a re-evaluation of how these chronic inflammatory illnesses are routinely treated. The standard of care for autoimmune disease remains the use of medications that slow the immune response, while treatments aimed at eradicating microbes seek the exact opposite—stimulation of the innate immune response. Immunostimulation is complicated by a cascade of sequelae, including exacerbated inflammation, | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | {{tag> |